Cargando…

Metformin for Preventing Progression From Prediabetes to Diabetes Mellitus in People Living With Human Immunodeficiency Virus

Background Diabetes mellitus (DM) and human immunodeficiency virus (HIV) itself increase the risk for cardiovascular diseases in people living with HIV (PLHIV). Prediabetes, a condition preceding DM, is common in PLHIV receiving antiretroviral therapy (ART). Both metformin and lifestyle intervention...

Descripción completa

Detalles Bibliográficos
Autores principales: Nimitphong, Hataikarn, Jiriyasin, Sitta, Kasemasawachanon, Pisekporn, Sungkanuparph, Somnuek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138719/
https://www.ncbi.nlm.nih.gov/pubmed/35651475
http://dx.doi.org/10.7759/cureus.24540
_version_ 1784714689954971648
author Nimitphong, Hataikarn
Jiriyasin, Sitta
Kasemasawachanon, Pisekporn
Sungkanuparph, Somnuek
author_facet Nimitphong, Hataikarn
Jiriyasin, Sitta
Kasemasawachanon, Pisekporn
Sungkanuparph, Somnuek
author_sort Nimitphong, Hataikarn
collection PubMed
description Background Diabetes mellitus (DM) and human immunodeficiency virus (HIV) itself increase the risk for cardiovascular diseases in people living with HIV (PLHIV). Prediabetes, a condition preceding DM, is common in PLHIV receiving antiretroviral therapy (ART). Both metformin and lifestyle interventions have been established to reduce the risk of progression from prediabetes to DM in the general population. This study aimed to evaluate the efficacy of metformin for preventing DM in prediabetic PLHIV. Methods An open-label randomized controlled clinical trial was conducted in HIV-positive persons with prediabetes. The participants were randomized into two groups: the metformin group (received metformin) and the control group (did not receive metformin). All participants were counseled regarding diet control and lifestyle modification and followed for 12 months. The primary endpoint was the development of DM. Fasting plasma glucose (FPG), two-hour plasma glucose (2-h PG) after 75 g oral glucose tolerance test (OGTT), hemoglobin A1c (HbA1c), and computer-based homeostatic model assessment index of beta-cell function (HOMA%B) and insulin resistance (HOMA-IR) were analyzed. Results Seventy-four participants were enrolled, 37 in each group. The mean age was 49.6 years, and 68.9% were males. At baseline, the mean CD4 cell count was 570 cells/mm(3), and the mean body mass index (BMI) was 24.6 kg/m(2). Baseline characteristics including age, sex, BMI, waist/hip ratio, duration of ART, ART regimen, CD4 cell count, and HIV RNA were similar between the two groups. The mean FPG, 2-h PG, HbA1c, HOMA%B, and HOMA-IR at baseline were also similar between the two groups. At 12 months, one participant in the metformin group and three in the control group developed DM (risk reduction: 5.41%; 95% confidence interval (CI): −6.92%-18.78%). When we compared changes in parameters between the two groups, there were trends toward more changes in HbA1c ([Formula: see text] HbA1c) at both six months (metformin group versus control group: -0.17% ± 0.20% versus 0.02% ± 0.58%; p = 0.074) and 12 months (metformin group versus control group: -0.05% ± 0.23% versus 0.06% ± 0.27%; p = 0.065). When we considered changes in all parameters in each group, the metformin group had significant reductions in body weight (BW) and BMI at both six and 12 months, and significant reductions in HbA1c and HOMA-IR at six months. No participant had adverse effects that led to the discontinuation of metformin. No cardiovascular event was observed during the study period. Conclusions Metformin tends to improve HbA1c and insulin resistance and may prevent progression from prediabetes to DM in HIV-positive persons with prediabetes. A further large study with a longer study period is needed to evaluate the long-term benefit of metformin.
format Online
Article
Text
id pubmed-9138719
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-91387192022-05-31 Metformin for Preventing Progression From Prediabetes to Diabetes Mellitus in People Living With Human Immunodeficiency Virus Nimitphong, Hataikarn Jiriyasin, Sitta Kasemasawachanon, Pisekporn Sungkanuparph, Somnuek Cureus Endocrinology/Diabetes/Metabolism Background Diabetes mellitus (DM) and human immunodeficiency virus (HIV) itself increase the risk for cardiovascular diseases in people living with HIV (PLHIV). Prediabetes, a condition preceding DM, is common in PLHIV receiving antiretroviral therapy (ART). Both metformin and lifestyle interventions have been established to reduce the risk of progression from prediabetes to DM in the general population. This study aimed to evaluate the efficacy of metformin for preventing DM in prediabetic PLHIV. Methods An open-label randomized controlled clinical trial was conducted in HIV-positive persons with prediabetes. The participants were randomized into two groups: the metformin group (received metformin) and the control group (did not receive metformin). All participants were counseled regarding diet control and lifestyle modification and followed for 12 months. The primary endpoint was the development of DM. Fasting plasma glucose (FPG), two-hour plasma glucose (2-h PG) after 75 g oral glucose tolerance test (OGTT), hemoglobin A1c (HbA1c), and computer-based homeostatic model assessment index of beta-cell function (HOMA%B) and insulin resistance (HOMA-IR) were analyzed. Results Seventy-four participants were enrolled, 37 in each group. The mean age was 49.6 years, and 68.9% were males. At baseline, the mean CD4 cell count was 570 cells/mm(3), and the mean body mass index (BMI) was 24.6 kg/m(2). Baseline characteristics including age, sex, BMI, waist/hip ratio, duration of ART, ART regimen, CD4 cell count, and HIV RNA were similar between the two groups. The mean FPG, 2-h PG, HbA1c, HOMA%B, and HOMA-IR at baseline were also similar between the two groups. At 12 months, one participant in the metformin group and three in the control group developed DM (risk reduction: 5.41%; 95% confidence interval (CI): −6.92%-18.78%). When we compared changes in parameters between the two groups, there were trends toward more changes in HbA1c ([Formula: see text] HbA1c) at both six months (metformin group versus control group: -0.17% ± 0.20% versus 0.02% ± 0.58%; p = 0.074) and 12 months (metformin group versus control group: -0.05% ± 0.23% versus 0.06% ± 0.27%; p = 0.065). When we considered changes in all parameters in each group, the metformin group had significant reductions in body weight (BW) and BMI at both six and 12 months, and significant reductions in HbA1c and HOMA-IR at six months. No participant had adverse effects that led to the discontinuation of metformin. No cardiovascular event was observed during the study period. Conclusions Metformin tends to improve HbA1c and insulin resistance and may prevent progression from prediabetes to DM in HIV-positive persons with prediabetes. A further large study with a longer study period is needed to evaluate the long-term benefit of metformin. Cureus 2022-04-27 /pmc/articles/PMC9138719/ /pubmed/35651475 http://dx.doi.org/10.7759/cureus.24540 Text en Copyright © 2022, Nimitphong et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Endocrinology/Diabetes/Metabolism
Nimitphong, Hataikarn
Jiriyasin, Sitta
Kasemasawachanon, Pisekporn
Sungkanuparph, Somnuek
Metformin for Preventing Progression From Prediabetes to Diabetes Mellitus in People Living With Human Immunodeficiency Virus
title Metformin for Preventing Progression From Prediabetes to Diabetes Mellitus in People Living With Human Immunodeficiency Virus
title_full Metformin for Preventing Progression From Prediabetes to Diabetes Mellitus in People Living With Human Immunodeficiency Virus
title_fullStr Metformin for Preventing Progression From Prediabetes to Diabetes Mellitus in People Living With Human Immunodeficiency Virus
title_full_unstemmed Metformin for Preventing Progression From Prediabetes to Diabetes Mellitus in People Living With Human Immunodeficiency Virus
title_short Metformin for Preventing Progression From Prediabetes to Diabetes Mellitus in People Living With Human Immunodeficiency Virus
title_sort metformin for preventing progression from prediabetes to diabetes mellitus in people living with human immunodeficiency virus
topic Endocrinology/Diabetes/Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138719/
https://www.ncbi.nlm.nih.gov/pubmed/35651475
http://dx.doi.org/10.7759/cureus.24540
work_keys_str_mv AT nimitphonghataikarn metforminforpreventingprogressionfromprediabetestodiabetesmellitusinpeoplelivingwithhumanimmunodeficiencyvirus
AT jiriyasinsitta metforminforpreventingprogressionfromprediabetestodiabetesmellitusinpeoplelivingwithhumanimmunodeficiencyvirus
AT kasemasawachanonpisekporn metforminforpreventingprogressionfromprediabetestodiabetesmellitusinpeoplelivingwithhumanimmunodeficiencyvirus
AT sungkanuparphsomnuek metforminforpreventingprogressionfromprediabetestodiabetesmellitusinpeoplelivingwithhumanimmunodeficiencyvirus